Medarex To Start Pivotal Trial Of MDX-010/Cancer Vaccine Combo For Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans a Subpart E filing as early as 2006 based on response rate data from the Phase III study, designed under a special protocol assessment with FDA. The immune-boosting MDX-010/MDX-1349 combination trial will start enrolling patients in September.
You may also be interested in...
Bristol To Devote $125 Mil. To Develop Medarex' Metastatic Melanoma Agent
Bristol adds Phase III anti-CTLA-4 product MDX-010 to its franchise as several of its oncologics are exposed to generic competition. Medarex cites upside potential as a reason for entering into the collaboration with Bristol.
Bristol To Devote $125 Mil. To Develop Medarex' Metastatic Melanoma Agent
Bristol adds Phase III anti-CTLA-4 product MDX-010 to its franchise as several of its oncologics are exposed to generic competition. Medarex cites upside potential as a reason for entering into the collaboration with Bristol.
Pfizer/Medarex Antibody Collaboration Includes Cross-Licensing Of Melanoma Products
Medarex expects cross-licensing anti-CTLA-4 products will enhance opportunities for future products by clearing up potential intellectual property issues. Pfizer will make up-front payments totaling $110 mil. to secure 50 antibody products over 10 years.